Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
Cancer combo trial pulled before it even started
Disease control TerminatedThis study was designed to test a new drug called IN10018 combined with chemotherapy and an immunotherapy for people with advanced solid tumors, like lung cancer, that had stopped responding to prior treatments. The goal was to see if the combination could shrink tumors or slow t…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug duo targets Tough-to-Treat cancers in early trial
Disease control OngoingThis early-phase study is testing a combination of two experimental drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 140 a…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC